查看购物车
  • Traditional Chinese
  • English
  • Japanese
肿瘤学中的单株抗体：全球市场
市场调查报告书
商品编码
1936027

肿瘤学中的单株抗体：全球市场

Monoclonal Antibodies for Oncology: Global Markets
出版日期: | 出版商: BCC Research | 英文 229 Pages | 订单完成后即时交付

价格

全球肿瘤单株抗体市场预计将从 2025 年的 1,293 亿美元成长到 2030 年底的 2,280 亿美元，在预测期（2025-2030 年）内以 12% 的复合年增长率成长。

预计北美市场将从 2025 年的 745 亿美元成长到 2030 年底的 1,322 亿美元，在预测期（2025-2030 年）内以 12.2% 的复合年增长率成长。

欧洲市场预计将从 2025 年的 292 亿美元成长到 2030 年底的 507 亿美元，在预测期内实现 11.7% 的复合年增长率。

本报告检视了肿瘤领域的全球单株抗体市场，并提供了市场概况、市场影响因素和市场机会分析、技术趋势、法律制度、市场规模趋势和预测、按各个细分市场和地区进行的详细分析以及主要企业的概况。

目录

第一章执行摘要

  • 市场展望
  • 调查范围
  • 市场概况
  • 市场动态与成长要素
  • 新兴技术
  • 细分市场分析
  • 区域分析
  • 结论

第二章 市场概览

  • 概述
  • 宏观经济因素分析
  • 美国关税对製药业的影响
  • 医疗费用
  • 高龄化社会
  • 地缘政治风险、贸易战和供应链中断
  • 全球经济成长（GDP）对製药业的影响
  • 波特五力分析

第三章 市场动态

  • 市场动态
  • 市场驱动因素
  • 癌症发生率加速上升
  • 肿瘤学领域未满足的医疗需求及单株抗体的作用
  • 企业研发支出增加
  • 政府增加拨款和医药品研究开发费用
  • 市场限制
  • 单株抗体高成本
  • 独特性丧失与一般化
  • 肿瘤专科医生短缺
  • 市场机会
  • 单株抗体在肿瘤学中的潜力
  • 新兴市场

第四章：监理现状

  • 概述
  • 我们
  • 欧洲
  • 亚太地区

第五章 新兴技术、临床试验分析与专利分析

  • 概述
  • AI
  • 免疫疗法和细胞疗法
  • 新兴生物标记
  • 临床试验分析
  • 按研究类型进行的临床试验分析
  • 临床试验分析：按状态
  • 临床试验分析：按阶段
  • 重点总结
  • 专利分析
  • 重点总结

第六章 市场区隔分析

  • 细分市场分析
  • 全球肿瘤单株抗体市场（按类型划分）
  • 重点总结
  • 人性化
  • 人类
  • 嵌合体
  • 全球肿瘤单株抗体市场（按癌症类型划分）
  • 重点总结
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 淋巴瘤
  • 白血病
  • 黑色素瘤
  • 多发性骨髓瘤
  • 其他癌症
  • 地理细分
  • 全球肿瘤单株抗体市场（按地区划分）
  • 重点总结
  • 北美洲
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东和非洲

第七章 竞争讯息

  • 重点总结
  • 竞争格局
  • 企业市场占有率分析

第八章 全球肿瘤单株抗体市场的永续性：ESG视角

  • ESG简介
  • 全球肿瘤单株抗体市场的永续性
  • ESG观点
  • 环境影响
  • 对社会的影响
  • 管治影响
  • ESG风险评估
  • 结论

第九章附录

  • 调查方法
  • 简称
  • 来源
  • 公司简介
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • GSK PLC
  • JAZZ PHARMACEUTICALS INC.
  • JOHNSON & JOHNSON
  • LILLY USA LLC.
  • MERCK & CO. INC.
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 新兴企业/市场颠覆者
Product Code: PHM261B

The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.

The North American market for monoclonal antibodies in oncology is expected to grow from $74.5 billion in 2025 and is projected to reach $132.2 billion by the end of 2030, at a CAGR of 12.2% during the forecast period of 2025 to 2030.

The European market for monoclonal antibodies in oncology is expected to grow from $29.2 billion in 2025 and is projected to reach $50.7 billion by the end of 2030, at a CAGR of 11.7% during the forecast period of 2025 to 2030.

Report Scope

The report provides detailed information on monoclonal antibodies in oncology. This report analyzes the market trends and includes global revenue ($ million) for the base year 2024, estimated data for 2025, and forecast data from 2025 through 2030. The report highlights the current and future market potential of monoclonal antibodies in oncology and provides a detailed analysis of the competitive environment. It includes regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key companies.

The market scope in this report is segmented by type, cancer type and region. By type, the market is segmented into humanized, human and chimeric. The cancer type segment is characterized into lung cancer, breast cancer, colorectal cancer, lymphoma, leukemia, melanoma, multiple myeloma and other cancers.

The region covered in this study includes North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment provides a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India.

The report aims to:

  • Analyze types of monoclonal antibodies in oncology.
  • Analyze global market size and segmentation.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts through 2030.
  • Assess market shares, competitiveness and industry structure.
  • Identify potential long-term impacts on the market for monoclonal antibodies in oncology.

Report Includes

  • 91 data tables and 59 additional tables
  • In-depth analysis of the global markets for monoclonal antibodies (mAbs) for oncology
  • Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
  • Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on type, cancer type and region
  • Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
  • Highlights of promising new advancements in monoclonal antibody-based nanoparticle therapy in cancer treatment, the emergence of next-generation therapeutic inhibitors, their potential and mechanism of action
  • Insights derived from Porter's Five Forces model, as well as global supply chain analyses
  • Review of the regulatory landscape featuring the U.S. premarket notifications and approvals with emphasis on recently approved products as well as products under development or in different stages of clinical trials
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • A relevant patent analysis, featuring key granted and published patents
  • Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
  • Profiles of the leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co., Johnson & Johnson Services, AstraZeneca, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Macroeconomic Factors Analysis
  • Impact of U.S. Tariffs on the Pharmaceutical Industry
  • Healthcare Expenditure
  • Aging Population
  • Geopolitical Risks, Trade Wars and Supply Chain Disruptions
  • Impact of Global Economic Growth (GDP) on the Pharmaceutical Sector
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Potential for New Entrants
  • Threat of Substitutes
  • Competitiveness in the Industry

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Acceleration in Cancer Rates
  • Unmet Treatment Need and the Role of Monoclonal Antibodies in Oncology
  • Increasing R&D Spending by Companies
  • Rise in Government Funding and Pharmaceutical R&D Spending
  • Market Restraints
  • High Cost of Monoclonal Antibodies
  • Loss of Exclusivity and Genericization
  • Shortage of Oncology Professionals
  • Market Opportunities
  • Potential of Monoclonal Antibodies in Oncology
  • Emerging Markets

Chapter 4 Regulatory Landscape

  • Overview
  • U.S.
  • Europe
  • Asia-Pacific

Chapter 5 Emerging Technologies, Clinical Trial Analysis and Patent Analysis

  • Overview
  • Artificial Intelligence (AI)
  • Immunotherapy and Cell Therapy
  • Emergent Biomarkers
  • Clinical Trial Analysis
  • Clinical Trials Analysis by Type of Study
  • Clinical Trials Analysis by Status
  • Clinical Trials Analysis by Phase
  • Key Takeaways
  • Patent Analysis
  • Key Takeaways

Chapter 6 Market Segmentation Analysis

  • Segmentation Breakdown
  • Global Market for Monoclonal Antibodies in Oncology, by Type
  • Key Takeaways
  • Humanized
  • Human
  • Chimeric
  • Global Market for Monoclonal Antibodies in Oncology, by Cancer Type
  • Key Takeaways
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Lymphoma
  • Leukemia
  • Melanoma
  • Multiple Myeloma
  • Other Cancers
  • Geographic Breakdown
  • Global Market for Monoclonal Antibodies in Oncology, by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 7 Competitive Intelligence

  • Key Takeaways
  • Competitive Landscape
  • Company Share Analysis

Chapter 8 Sustainability in the Global Market for Monoclonal Antibodies in Oncology: An ESG Perspective

  • Introduction to ESG
  • Sustainability in the Global Market for Monoclonal Antibodies in Oncology
  • ESG Perspective
  • Environmental Impact
  • Social Impact
  • Governance Impact
  • ESG Risk Ratings
  • Conclusion

Chapter 9 Appendix

  • Methodology
  • Abbreviations
  • Sources
  • Company Profiles
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • GSK PLC
  • JAZZ PHARMACEUTICALS INC.
  • JOHNSON & JOHNSON
  • LILLY USA LLC.
  • MERCK & CO. INC.
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Emerging Companies/Market Disruptors

List of Tables

  • Summary Table : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 1 : Current Health Expenditure, by Country, 2021-2023
  • Table 2 : National Cancer Institute Funding, by Mechanism, 2020-2024
  • Table 3 : Average Price of a Few Monoclonal Antibodies
  • Table 4 : Few Approved Biosimilars in the Market
  • Table 5 : Clinical Trials in Monoclonal Antibodies in Oncology, by Type of Study, as of September 2025
  • Table 6 : Clinical Trials in Monoclonal Antibodies in Oncology, by Status, as of September 2025
  • Table 7 : Clinical Trials in Monoclonal Antibodies in Oncology, by Phase, as of September 2025
  • Table 8 : List of Selected Monoclonal Antibodies Clinical Trials Studies
  • Table 9 : List of Selected Recent Patents Related to Monoclonal Antibodies, 2024 - 2025
  • Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 11 : Top Humanized mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023-2024
  • Table 12 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 13 : Top Human mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023 - 2024
  • Table 14 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 15 : Top Chimeric mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023 - 2024
  • Table 16 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 17 : Global Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 18 : Global Market for Lung Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 19 : Global Market for Breast Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 20 : Global Market for Colorectal Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 21 : Global Market for Lymphoma in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 22 : Global Market for Leukemia in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 23 : Global Market for Melanoma in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 24 : Global Market for Multiple Myeloma in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 25 : Global Market for Other Cancers in Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 26 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 27 : North American Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 28 : North American Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 29 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
  • Table 30 : U.S. Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 31 : U.S. Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 32 : Canadian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 33 : Canadian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 34 : Mexican Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 35 : Mexican Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 36 : European Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 37 : European Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 38 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
  • Table 39 : German Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 40 : German Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 41 : U.K. Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 42 : U.K. Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 43 : French Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 44 : French Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 45 : Italian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 46 : Italian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 47 : Spanish Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 48 : Spanish Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 49 : Rest of Europe Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 50 : Rest of Europe Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 51 : Cancer Cases in Asia-Pacific, by Sub-Region, 2022
  • Table 52 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 53 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 54 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
  • Table 55 : Chinese Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 56 : Chinese Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 57 : Japanese Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 58 : Japanese Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 59 : Indian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 60 : Indian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 61 : South Korean Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 62 : South Korean Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 63 : Australian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 64 : Australian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 65 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 66 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 67 : Cancer Cases in Selected South American Countries, 2022
  • Table 68 : South American Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 69 : South American Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 70 : South American Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
  • Table 71 : Brazilian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 72 : Brazilian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 73 : Argentinian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 74 : Argentinian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 75 : Rest of South America Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 76 : Rest of South America Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 77 : MEA Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 78 : MEA Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 79 : MEA Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
  • Table 80 : Middle East Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 81 : Middle East Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 82 : Approved mAbs in African Countries
  • Table 83 : African Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
  • Table 84 : African Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
  • Table 85 : Key Strategic Initiatives in Global Market for Monoclonal Antibodies in Oncology, 2024 - 2025
  • Table 86 : Key Focus Areas in ESG Metrics
  • Table 87 : ESG Rankings for Leading Companies in Monoclonal Antibodies in Oncology, 2025*
  • Table 88 : Abbreviations Used in this Report
  • Table 89 : Report Sources
  • Table 90 : AbbVie Inc.: Company Snapshot
  • Table 91 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
  • Table 92 : AbbVie Inc.: Product Portfolio
  • Table 93 : AbbVie Inc.: News/Key Developments, 2023-2025
  • Table 94 : Amgen Inc.: Company Snapshot
  • Table 95 : Amgen Inc.: Financial Performance, FY 2023 and 2024
  • Table 96 : Amgen Inc.: Product Portfolio
  • Table 97 : Amgen Inc.: News/Key Developments, 2022-2025
  • Table 98 : AstraZeneca: Company Snapshot
  • Table 99 : AstraZeneca: Financial Performance, FY 2023 and 2024
  • Table 100 : AstraZeneca: Product Portfolio
  • Table 101 : AstraZeneca: News/Recent Developments, 2023-2025
  • Table 102 : Bristol-Myers Squibb Co.: Company Snapshot
  • Table 103 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
  • Table 104 : Bristol-Myers Squibb Co.: Product Portfolio
  • Table 105 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
  • Table 106 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 107 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
  • Table 108 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 109 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
  • Table 110 : Gilead Sciences Inc.: Company Snapshot
  • Table 111 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
  • Table 112 : Gilead Sciences Inc.: Product Portfolio
  • Table 113 : Gilead Sciences Inc.: News/Key Developments, 2023-2024
  • Table 114 : GSK plc: Company Snapshot
  • Table 115 : GSK plc: Financial Performance, FY 2023 and 2024
  • Table 116 : GSK plc: Product Portfolio
  • Table 117 : GSK plc: News/Key Developments, 2023-2025
  • Table 118 : Jazz Pharmaceuticals Inc.: Company Snapshot
  • Table 119 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
  • Table 120 : Jazz Pharmaceuticals Inc.: Product Portfolio
  • Table 121 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2024-2025
  • Table 122 : Johnson & Johnson: Company Snapshot
  • Table 123 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
  • Table 124 : Johnson & Johnson: Product Portfolio
  • Table 125 : Johnson & Johnson.: News/Key Developments, 2022-2025
  • Table 126 : Lilly USA LLC.: Company Snapshot
  • Table 127 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
  • Table 128 : Lilly USA LLC.: Product Portfolio
  • Table 129 : Lilly USA LLC.: News/Key Development, 2022-2023
  • Table 130 : Merck & Co. Inc.: Company Snapshot
  • Table 131 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
  • Table 132 : Merck & Co. Inc.: Product Portfolio
  • Table 133 : Merck & Co. Inc.: News/Key Developments, 2022-2025
  • Table 134 : Pfizer Inc.: Company Snapshot
  • Table 135 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
  • Table 136 : Pfizer Inc.: Product Portfolio
  • Table 137 : Pfizer Inc.: News/Key Developments, 2023-2025
  • Table 138 : Regeneron Pharmaceuticals Inc.: Company Snapshot
  • Table 139 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
  • Table 140 : Regeneron Pharmaceuticals Inc.: Product Portfolio
  • Table 141 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
  • Table 142 : Sanofi: Company Snapshot
  • Table 143 : Sanofi: Financial Performance, FY 2023 and 2024
  • Table 144 : Sanofi: Product Portfolio
  • Table 145 : Sanofi: News/Key Developments, 2022-2025
  • Table 146 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
  • Table 147 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
  • Table 148 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
  • Table 149 : A Few Emerging Companies in the Global Market for Monoclonal Antibodies in Oncology

List of Figures

  • Summary Figure : Global Market Shares for Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 1 : Porter's Five Forces Analysis of the Global Market for Monoclonal Antibodies in Oncology
  • Figure 2 : Market Dynamics of Monoclonal Antibodies in Oncology
  • Figure 3 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
  • Figure 4 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
  • Figure 5 : Estimated New Cancer Cases and Deaths in the U.S., 2024
  • Figure 6 : Share of Companies' R&D Expenditure, by Function, 2022
  • Figure 7 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
  • Figure 8 : Global Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 9 : Global Market Shares for Humanized Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 10 : Global Market Shares for Human Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 11 : Global Market Shares for Chimeric Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 12 : Global Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 13 : Global Market Shares for Lung Cancer in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 14 : Global Market Shares for Breast Cancer in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 15 : Global Market Shares for Colorectal Cancer in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 16 : Global Market Shares for Lymphoma in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 17 : Global Market Shares for Leukemia in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 18 : Global Market Shares for Melanoma in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 19 : Global Market Shares for Multiple Myeloma in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 20 : Global Market Shares for Other Cancers in Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 21 : Global Market Shares for Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 22 : North American Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 23 : North American Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 24 : North American Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
  • Figure 25 : U.S. Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 26 : U.S. Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 27 : Canadian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 28 : Canadian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 29 : Mexican Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 30 : Mexican Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 31 : European Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 32 : European Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 33 : European Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
  • Figure 34 : German Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 35 : German Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 36 : U.K. Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 37 : U.K. Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 38 : French Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 39 : French Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 40 : Italian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 41 : Italian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 42 : Spanish Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 43 : Spanish Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 44 : Rest of Europe Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 45 : Rest of Europe Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 46 : Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 47 : Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 48 : Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
  • Figure 49 : Chinese Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 50 : Chinese Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 51 : Japanese Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 52 : Japanese Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 53 : Indian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 54 : Indian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 55 : South Korean Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 56 : South Korean Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 57 : Australian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 58 : Australian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 59 : Rest of Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 60 : Rest of Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 61 : South American Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 62 : South American Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 63 : South American Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
  • Figure 64 : Brazilian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 65 : Brazilian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 66 : Argentinian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 67 : Argentinian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 68 : Rest of South America Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 69 : Rest of South America Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 70 : MEA Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 71 : MEA Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 72 : MEA Market Shares for Monoclonal Antibodies in Oncology, by Region, 2024
  • Figure 73 : Middle East Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 74 : Middle East Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 75 : African Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
  • Figure 76 : African Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
  • Figure 77 : Top 10 Blockbuster Monoclonal Antibodies in Oncology, by Sales Revenue, 2023-2024
  • Figure 78 : Global Market Shares for Monoclonal Antibodies in Oncology, by Company, 2024
  • Figure 79 : Pillars of ESG
  • Figure 80 : Advantages of ESG for Companies
  • Figure 81 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 82 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
  • Figure 83 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 84 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
  • Figure 85 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
  • Figure 86 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
  • Figure 87 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
  • Figure 88 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
  • Figure 89 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
  • Figure 90 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
  • Figure 91 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 92 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
  • Figure 93 : GSK plc: Revenue Shares, by Business Unit, FY 2024
  • Figure 94 : GSK plc: Revenue Shares, by Country/Region, FY 2024
  • Figure 95 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 96 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
  • Figure 97 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
  • Figure 98 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
  • Figure 99 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
  • Figure 100 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
  • Figure 101 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 102 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
  • Figure 103 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 104 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
  • Figure 105 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
  • Figure 106 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 107 : Sanofi: Revenue Shares, by Country/Region, FY 2024
  • Figure 108 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2024